An Open-Label Study of Belumosudil, a Selective ROCK2 Inhibitor, As Second or Subsequent Line of Therapy for Steroid-Dependent/steroid-resistant Chronic GVHD.
American Journal of Hematology（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined